XRD-0394

DRUG2 trials

Sponsors

XRad Therapeutics Inc, NYU Langone Health

Conditions

High-Grade GliomaLocally Advanced Solid TumorMetastasisRecurrent Cancer

Early Phase 1

Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas

RecruitingNCT06829173

NYU Langone HealthHigh-Grade Glioma

Start: 2025-11-05End: 2031-05-31Target: 39Updated: 2026-01-02

Phase 1

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

CompletedNCT05002140

XRad Therapeutics IncLocally Advanced Solid Tumor, Metastasis, Recurrent Cancer

Start: 2021-08-24End: 2023-07-21Updated: 2024-01-11

Related Papers

A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors

Molecular Cancer Therapeutics2024-04-0820 citations

Abstract LB181: First disclosure of XRD-0394, a novel dual ATM/DNA-PK inhibitor, that potently radiosensitizes and potentiates PARP and topoisomerase inhibitors

Cancer Research2024-04-052 citations